• Alnylam Pharmaceuticals recently expanded its Board of Directors from ten to eleven members and appointed Benjamin F. Cravatt, Ph.D., as a Class III director through 2028, also adding him to its Science and Technology Committee.
• His appointment brings additional scientific expertise to the boardroom at a time when Alnylam’s RNA interference pipeline and ATTR-CM program are under heightened investor scrutiny following new clinical data and fresh analyst coverage.
• Next, we’ll examine how Citi’s coverage initiation following new HELIOS-B data on vutrisiran could reshape Alnylam’s existing investment narrative.

The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Alnylam Pharmaceuticals Investment Narrative Recap

To own Alnylam, you need to be comfortable with a story centered on RNA interference leadership and a heavily TTR‑weighted revenue base, where AMVUTTRA and vutrisiran remain the key value drivers. The most important near term catalyst is how HELIOS‑B data on vutrisiran for ATTR‑CM ultimately converts into prescribing patterns and payer decisions. The Cravatt board appointment does not materially change that catalyst or the near term risk profile around pricing, margins, or TTR concentration.

What does tie closely to today’s debate is Citi’s recent initiation of coverage following the new HELIOS‑B analyses, highlighting vutrisiran’s clinical profile in ATTR‑CM. That report squarely intersects with the core catalyst for the stock: whether Alnylam can translate its ATTR‑CM data into durable first line use without worsening price pressure or overextending its TTR reliance. How that balance evolves will likely matter more than incremental governance changes for near term sentiment.

Yet against this opportunity, investors should be aware that concentrated dependence on the TTR franchise means...

Alnylam Pharmaceuticals’ narrative projects $7.0 billion revenue and $1.9 billion earnings by 2028.

Uncover how Alnylam Pharmaceuticals' forecasts yield a $491.92 fair value, a 61% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts, who were only assuming about US$8.5 billion of revenue and US$1.3 billion of earnings by 2029, paint a much tougher picture than consensus, so it is worth weighing their concerns about TTR dependence and pricing pressure alongside the recent HELIOS‑B momentum.

Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.